MSH6 and colorectal carcinoma: BRAF testing was of no value in EC and was abandoned for the PETALS study.25 The difference in path_MMR variant rates between CRC and EC was most striking for MSH6 with pathogenic variants identified in 24/44 (54.5%) cases of EC compared with 21/155 (13.5%) for CRC (p<0.0001).